Christopher J Larocca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7089059/publications.pdf

Version: 2024-02-01

24 papers 457 citations

949033 11 h-index 799663 21 g-index

24 all docs

24 docs citations

24 times ranked 791 citing authors

#	Article	IF	CITATIONS
1	The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases. Cancer Control, 2022, 29, 107327482211099.	0.7	O
2	A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. Journal of Surgical Oncology, 2021, 123, 187-195.	0.8	4
3	Robotic assistance for quick and accurate image-guided needle placement. Updates in Surgery, 2021, 73, 1197-1201.	0.9	7
4	Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion. Molecular Therapy - Oncolytics, 2021, 20, 659-668.	2.0	7
5	Interferon Alpha-Expressing Oncolytic Adenovirus for Treatment of Esophageal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 8556-8564.	0.7	6
6	ASO Visual Abstract: Interferon Alpha-Expressing Oncolytic AdenovirusÂfor the Treatment ofÂEsophageal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 565-566.	0.7	0
7	The New Normal? Patient Satisfaction and Usability of Telemedicine in Breast Cancer Care. Annals of Surgical Oncology, 2021, 28, 5668-5676.	0.7	44
8	ASO Author Reflections: The Role of Oncolytic Virotherapy in Advanced Gastrointestinal Cancers. Annals of Surgical Oncology, 2021, 28, 8565-8566.	0.7	0
9	Subungual Melanoma: A Single Institution Experience. Medical Sciences (Basel, Switzerland), 2021, 9, 57.	1.3	3
10	ASO Visual Abstract: The New Normal? Patient Satisfaction and Usability of Telemedicine in Breast Cancer Care. Annals of Surgical Oncology, 2021, 28, 676-677.	0.7	2
11	Academic Productivity in Hepatopancreatobiliary Surgeons: Identifying Benchmarks Associated With Rank in North America. American Surgeon, 2021, 87, 1474-1479.	0.4	1
12	Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. Cancers, 2020, 12, 1295.	1.7	28
13	The impact of financial toxicity in gastrointestinal cancer patients. Surgery, 2020, 168, 167-172.	1.0	15
14	What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. Clinical Colorectal Cancer, 2020, 19, e1-e7.	1.0	14
15	Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds. Molecular Therapy - Oncolytics, 2019, 13, 93-106.	2.0	107
16	Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clinical and Translational Medicine, 2018, 7, 35.	1.7	96
17	A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer. Biomedicines, 2018, 6, 104.	1.4	13
18	Academic productivity in surgical oncology: Where is the bar set for those training the next generation?. Journal of Surgical Oncology, 2018, 118, 397-402.	0.8	12

#	Article	IF	CITATIONS
19	Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer. Oncotarget, 2018, 9, 18041-18052.	0.8	32
20	Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts. Biomedicines, 2016, 4, 23.	1.4	10
21	Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas. Oral Oncology, 2016, 56, 25-31.	0.8	12
22	Oncolytic Virotherapy Increases the Detection of Microscopic Metastatic Disease at Time of Staging Laparoscopy for Pancreatic Adenocarcinoma. EBioMedicine, 2016, 7, 15-16.	2.7	3
23	Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal cancer: choosing the right candidates. Expert Review of Anticancer Therapy, 2015, 15, 859-861.	1.1	1
24	Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment ofÂpancreatic cancer. Surgery, 2015, 157, 888-898.	1.0	40